Background On 26 July 2024, the Committee for Medicinal Products for Human use (CHMP) of the European Medicines Agency (EMA) issued a negative opinion on the marketing authorisation application of...
Policy positions
From time to time, Alzheimer Europe will respond to developments in the fields of health, research and social policy, in order to constructively contribute to ongoing policy dialogues. Our policy positions are develop in collaboration with our members, as well as often involving and seeking the input of relevant experts in other sectors. By developing these opinions in a collaborative and consensual manner, it is our hope that the opinions provide useful offer guidance and/or recommendations for professionals, policy makers and other organisations.
In this section you will find our policy positions on a number of issues and responses to relevant policy papers and proposals.
Background On 8 December 2023, In the framework of its Strategic Action Plan on Human Rights and Technologies in Biomedicine (2020-2025), the Steering committee for human rights in the fields...
Background The growing prevalence and burden of Alzheimer’s disease has catalysed huge investments in research on its causes, diagnosis, treatment and care. After many high-profile failures, recent clinical trials of...
In a new position statement, and following engagement with its national members and the European Dementia Carers Working Group (EDCWG), Alzheimer Europe calls for open, honest, empathetic and compassionate disclosure...
Background On 18 January 2023, the European Commission published a Call for Evidence in relation to a proposed initiative on a comprehensive approach to mental health. The initiative had been...
Background On 1 December 2022, the European Commission opened a call for evidence on the proposed EU Disability Card. The card aims facilitate free movement for people with disabilities in...
Background On 12 May, Alzheimer Europe, the European Federation of Neurological Socieities (EFNA) and GAMIAN Europe held an onlnie summit to launch a joint Call for Action, highlighting the need...
Background On 1 March 2022, the European Commission issued a call for evidence on the development of a European Care Strategy, which aims to strengthen long-term care and early childhood...
Background On 17 December 2021, the European Medicines Agency (EMA), in a decision closely watched by the European dementia community, decided not to authorise aducanumab for the treatment of mild...
Background On 28 June 2022, the European Commission held a Strategic Dialogue meeting on the Employment and Social Innovation (EaSI) strand of the ESF+ Annual Work Programme 2024, inviting relevant...
Background Since the World Health Organization (WHO) identified COVID-19 as a global pandemic in March 2020, COVID-19 has claimed the lives of almost 670,000 people in the EU/EEA, with over...
Background On 23 February 2021, Alzheimer Europe published a report, "Data sharing in dementia research - the EU landscape", exploring the challenges of the data sharing in the field of...
Background In January 2021, as part of its work around demographic change in the EU, the European Commission published its "Green Paper on Ageing", launching a broad policy debate to...
Introduction In June 2021, the European Commission (DG SANTE) published a consultation on the future 2022 Annual Work Programme of the EU4Health programme. Alzheimer Europe completed the consultation survey, however...
Background In November 2020, the Seventy-third World Health Assembly (WHA) adopted resolution WHA 73.10 on Global actions on epilepsy and other neurological disorders, which requested the WHO Director-General to develop...
Background Alzheimer Europe responded to the WHO consultation on its initial draft of the WHO intersectoral Global Action Plan on Epilepsy and Other Neurological Disorders on 4 August 2021. Overview...
Background In light of the current COVID-19 pandemic, governments across Europe are taking measures to protect the health, wellbeing and lives of millions of inhabitants in relation to current and...
Background Alzheimer Europe and the undersigned organisations have come together to address the serious challenges facing the dementia research community which has been severely impacted by the COVID-19 pandemic. The...
Introduction The current coronavirus (COVID-19) situation, which has now reached pandemic scale, is affecting millions of people across Europe and beyond in different ways. Physical distancing (frequently referred to as...
Background Alzheimer Europe welcomes the possibility of collaborating with other organisations and the following principles provide the policy of the organisation for such collaborations. This policy is for the collaboration...
Background It is essential that patient and public involvement (PPI) is conducted in such a way that it promotes a meaningful and active involvement of people with dementia in research...
This page contains an abridged version of the position paper on how to improve legal rights and protection of people with incapacity. The full paper can be downloaded as a...
Background The present paper constitutes the position of Alzheimer Europe and its national member organisations on the availability of anti-dementia drugs and their reimbursement under national health systems. This position...
Overview of Alzheimer Europe's position Alzheimer Europe's position on stem cell research is as follows: Alzheimer Europe and its member organisations welcome scientific research that will increase the understanding of...
Background The Hague Convention of 13 January 2000 on the International Protection of Adults (HCCH 2000 Protection of Adults Convention) provides for the protection in international situations of adults who...
Executive Summary The purpose of this document is to present Alzheimer Europe’s position on the disclosure of the diagnosis of dementia to people with dementia and their carers. This position...
Background The present paper constitutes the input of Alzheimer Europe and its member organisations to the ongoing discussions within Europe about advance directives (in the context of Alzheimer’s disease and...
Background The position paper sets out the position of Alzheimer Europe and its member organisations in relation to genetic testing (in the context of Alzheimer's disease and other forms of...
Background This position paper sets out the position of Alzheimer Europe and its member organisations in relation to the involvement of people with dementia in clinical trials in Europe. This...
Background The present paper constitutes the input of Alzheimer Europe and its member organisations to the ongoing discussions about the participation of people with dementia in research and in particular...